{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:05:54Z","timestamp":1790024754592,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40257-026-01019-0","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:34:40Z","timestamp":1773318880000},"page":"479-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Icotrokinra: An Oral Interleukin-23 Receptor Antagonist Peptide for the Treatment of Psoriasis"],"prefix":"10.1007","volume":"27","author":[{"given":"C\u00e9sar","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"1","key":"1019_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45\u201345. https:\/\/doi.org\/10.1038\/s41572-025-00630-5.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1019_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313. https:\/\/doi.org\/10.4049\/jimmunol.1800013.","journal-title":"J Immunol"},{"key":"1019_CR3","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-5-6","volume":"13","author":"O Yilmaz","year":"2024","unstructured":"Yilmaz O, Pinto JP, Torres T. New and emerging oral therapies for psoriasis. Drugs Context. 2024;13:2024-5-6. https:\/\/doi.org\/10.7573\/dic.2024-5-6.","journal-title":"Drugs Context"},{"issue":"7","key":"1019_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/13543784.2023.2242767","volume":"32","author":"L Rusi\u00f1ol","year":"2023","unstructured":"Rusi\u00f1ol L, Carmona-Rocha E, Puig L. Psoriasis: A focus on upcoming oral formulations. Expert Opin Investig Drugs. 2023;32(7):583\u2013600. https:\/\/doi.org\/10.1080\/13543784.2023.2242767. (Epub 2023 Aug 1).","journal-title":"Expert Opin Investig Drugs"},{"key":"1019_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. https:\/\/doi.org\/10.3389\/fimmu.2024.1331217.","journal-title":"Front Immunol"},{"issue":"2","key":"1019_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173\u201392. https:\/\/doi.org\/10.1007\/s40257-020-00578-0.","journal-title":"Am J Clin Dermatol"},{"issue":"10148","key":"1019_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6.","journal-title":"Lancet"},{"issue":"3","key":"1019_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"10091","key":"1019_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, et al. Tildrakizumab versus PBO or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(17)31279-5.","journal-title":"Lancet"},{"key":"1019_CR10","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s13555-025-01454-7","volume":"15","author":"B Knight","year":"2025","unstructured":"Knight B, Tammara B, Modi NB, et al. Translational pharmacokinetics of icotrokinra, a targeted oral peptide that selectively blocks Interleukin-23 receptor and inhibits signaling. Dermatol Ther (Heidelb). 2025;15:2495\u2013520. https:\/\/doi.org\/10.1007\/s13555-025-01454-7.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1019_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67371-5","volume":"14","author":"AM Fourie","year":"2024","unstructured":"Fourie AM, Cheng X, Chang L, et al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024;14:17515. https:\/\/doi.org\/10.1038\/s41598-024-67371-5.","journal-title":"Sci Rep"},{"key":"1019_CR12","unstructured":"Johnson & Johnson. Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm. 2025. https:\/\/www.jnj.com\/innovativemedicine\/emea\/media-center\/press-releases\/johnson-johnson-seeks-first-european-medicines-agency-approval-for-icotrokinra-aiming-to-transform-the-plaque-psoriasis-treatment-paradigm."},{"issue":"10510","key":"1019_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","volume":"406","author":"LS Gold","year":"2025","unstructured":"Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(25)01576-4. (Epub 2025 Sep 18.).","journal-title":"Lancet"},{"issue":"18","key":"1019_CR14","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","volume":"393","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moore AY, et al. Oral Icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2504187.","journal-title":"N Engl J Med"},{"key":"1019_CR15","unstructured":"Soung J, Cui Y (J), Bissonnette, R, Lebwohl M, Gonz\u00e1lez-Cantero \u00c1, Pinter A, Rich P, Prajapati VH, Miller M, Cafone J, Jiang J, Li S, DeKlotz C, Yang Y-W, Pink AE. Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults (weeks 24\u201352) and continuous treatment in adolescents (through week 52) from the Phase 3, ICONIC-LEAD trial (Abstract No. LBA-183). Abstract presented at the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), Paris, France. 2025."},{"key":"1019_CR16","doi-asserted-by":"crossref","unstructured":"Eichenfield LF, Galimberti R, Hebert AA, Wang W, Soung J, Magnolo N, Browning J, Moore A, Lebwohl M, Wilsmann-Theis D, Kokolakis G, Mortazawi D, Grewal P, Miller M, Cafone J, Li S, Jiang G, Nunes F, DeKlotz C, Paller AS. Efficacy and safety of icotrokinra, a novel targeted oral peptide (IL-23R inhibitor), in adolescents with moderate-to-severe plaque psoriasis: subgroup analyses from the phase 3, randomized, double-blind, placebo-controlled ICONIC-LEAD study. Presented at: European Academy of Dermatology and Venereology (EADV) Congress; 2025 Sep 17\u201320; Paris, France. Also presented at: World Congress of Pediatric Dermatology (WCPD); 2025 Apr 8\u201311; Buenos Aires, Argentina. Sponsored by Johnson & Johnson.","DOI":"10.1016\/j.jid.2025.09.207"},{"issue":"12","key":"1019_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500155","volume":"4","author":"M Gooderham","year":"2025","unstructured":"Gooderham M, Lain E, Bissonnette R, Huang YH, Lynde CW, Hoffmann M, et al. Targeted oral peptide Icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025;4(12):EVIDoa2500155. https:\/\/doi.org\/10.1056\/EVIDoa2500155. (Epub 2025 Nov 5).","journal-title":"NEJM Evid"},{"key":"1019_CR18","unstructured":"Lain E, Warren RB, Gooderham M, et al. Durability of response to the targeted oral peptide icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings. Poster presented at: Fall Clinical Dermatology Conference; October 23-26, 2025; Las Vegas, NV."},{"key":"1019_CR19","unstructured":"National Library of Medicine (US). NCT06934226. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 1]. https:\/\/clinicaltrials.gov\/study\/NCT06934226."},{"issue":"6","key":"1019_CR20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","volume":"390","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, et al. An oral interleukin-23\u2013receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390(6):510\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2308713.","journal-title":"N Engl J Med"},{"key":"1019_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.076","author":"LK Ferris","year":"2024","unstructured":"Ferris LK, Bagel J, Huang Y-H, Pink AE, Tyring SK, Kokolakis G, et al. FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.076.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"1019_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.193563","volume":"10","author":"D Strawn","year":"2025","unstructured":"Strawn D, Krueger JG, Bissonnette R, Eyerich K, Ferris LK, Paller AS, et al. Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis. JCI Insight. 2025;10(24):e193563. https:\/\/doi.org\/10.1172\/jci.insight.193563.","journal-title":"JCI Insight"},{"key":"1019_CR23","unstructured":"National Library of Medicine (US). NCT06295692. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 1]. https:\/\/clinicaltrials.gov\/study\/NCT06295692."},{"key":"1019_CR24","unstructured":"National Library of Medicine (US). NCT06878404. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 1]. https:\/\/clinicaltrials.gov\/study\/NCT06878404."},{"key":"1019_CR25","unstructured":"National Library of Medicine (US). NCT06807424. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 1]. https:\/\/clinicaltrials.gov\/study\/NCT06807424."},{"key":"1019_CR26","unstructured":"National Library of Medicine (US). NCT06049017. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 1]. https:\/\/clinicaltrials.gov\/study\/NCT06049017."},{"key":"1019_CR27","unstructured":"National Library of Medicine (US). NCT07196748. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 1]. https:\/\/clinicaltrials.gov\/study\/NCT07196748."},{"key":"1019_CR28","unstructured":"National Library of Medicine (US). NCT07196722. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); [cited 2025 Oct 1]. https:\/\/clinicaltrials.gov\/study\/NCT07196722."},{"issue":"2","key":"1019_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.36469\/9817","volume":"4","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Holmen Moeller A, Erntoft Idemyr ST, Gonz\u00e1lez JM. Relative importance of mode of administration in treatment preferences among plaque psoriasis patients in the United States. J Health Econ Outcomes Res. 2016;4(2):141\u201357. https:\/\/doi.org\/10.36469\/9817.","journal-title":"J Health Econ Outcomes Res"},{"issue":"10510","key":"1019_CR30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(25)01675-7","volume":"406","author":"L Puig","year":"2025","unstructured":"Puig L. Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy. Lancet. 2025;406(10510):1316\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(25)01675-7.","journal-title":"Lancet"},{"issue":"6","key":"1019_CR31","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/1346-8138.16746","volume":"50","author":"M Komine","year":"2023","unstructured":"Komine M, Kim H, Yi J, Zhong Y, Sakai Y, Crawford B, et al. A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan. J Dermatol. 2023;50(6):766\u201377. https:\/\/doi.org\/10.1111\/1346-8138.16746.","journal-title":"J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01019-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01019-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01019-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:42:40Z","timestamp":1778661760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01019-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01019-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C\u00e9sar Ferreira has no conflicts of interest. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Apogee, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Oruka, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, Sun Pharma, Takeda, and UCB. Tiago Torres is an Editorial Board member of\n                      American Journal of Clinical Dermatology\n                      . Tiago Torres was not involved in the selection of peer reviewers for this manuscript nor in any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable. This article is a narrative review of published literature and does not involve original studies with human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable. All data discussed in this review are derived from previously published sources, which are cited in the reference list.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"CF contributed to the conception of the review, literature search, data interpretation, and drafting of the manuscript. TT contributed to the conception and supervision of the work, critical revision of the manuscript for important intellectual content, and final approval. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}